Takeda resubmits new drug applications for Type 2 diabetes treatments
OSAKA, Japan — Japanese drug maker Takeda Pharmaceutical is reapplying for approval of two drugs to treat Type 2 diabetes after the Food and Drug Administration turned down its last applications, the company said.
Takeda announced that it resubmitted its applications for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in Actos, which the FDA approved in 1999.
The FDA will review the applications over the next six months, the drug maker said.
Impax enrolls patients into late-stage trial for Parkinson’s treatment
HAYWARD, Calif. — The branded drugs division of Impax Labs has finished enrolling patients in a late-stage trial of a drug for Parkinson’s disease.
Impax Pharmaceuticals said Tuesday that it had enrolled patients in ASCEND-PD, a phase-3 trial of IPX066 that will compare the drug with carbidopa-levodopa and entacapone in patients with advanced Parkinson’s. IPX066 is an extended-release formulation of carbidopa-levodopa in capsule form.
“We are extremely pleased to have completed enrollment in ASCEND-PD, which is the third phase-3 trial of IPX066 in [Parkinson’s disease] subjects,” Impax Pharmaceuticals chief scientific officer Suneel Gupta said. “The study compares IPX066 to another commonly used medication in advanced PD and is intended to provide further safety and efficacy data on IPX066.”
Access, Walgreens broaden relationship to reach underserved populations
CHICAGO — Access Community Health Network and Walgreens have extended their relationship to co-develop an integrated program to provide accessible preventive and primary health care for underserved populations, Access said Monday.
As part of the partnership, Walgreens will work with Access on the following initiatives:
Create a pharmacy and therapeutics committee that will provide prescribing guidelines for all Access health centers to help every patient receive cost-effective, high-quality drug therapies;
Integrate a clinical pharmacy resident with Access’ physicians and nurses at one of Access’ health centers on Chicago’s South Side; and
Open a pharmacy inside the Access Genesis Center for Health and Empowerment health center in Des Plaines, Ill., which predominantly cares for an underserved Hispanic population.
Walgreens currently performs pharmacy services for Access’ more than 50 health centers that participate in the federal 340B program, which offers deep discounts on prescription medications to some of the nation’s most vulnerable patient populations, Access said.
"We are working with Walgreens to co-develop an integrated program that will ease the transition of our patients from in-patient facilities to enjoying healthy lives in the community and preventing hospital readmissions," Access CEO Donna Thompson said. "Through all of these Walgreens initiatives, Access will be better able to meet the needs of patients who often have nowhere else to turn for treatment."